BSR_10_0136_B1_S95
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.630
- IL6_JAK_STAT3_SIGNALING+0.490
- INTERFERON_GAMMA_RESPONSE+0.480
- INFLAMMATORY_RESPONSE+0.390
- INTERFERON_ALPHA_RESPONSE+0.350
- KRAS_SIGNALING_UP+0.340
- COMPLEMENT+0.290
- G2M_CHECKPOINT+0.260
- TNFA_SIGNALING_VIA_NFKB+0.230
- E2F_TARGETS+0.200
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.510
- ESTROGEN_RESPONSE_LATE-0.420
- ANGIOGENESIS-0.380
- TGF_BETA_SIGNALING-0.370
- PROTEIN_SECRETION-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- ADIPOGENESIS-0.260
- MYC_TARGETS_V2-0.260
- DNA_REPAIR-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1OV-01A-11R-A144-07 | — | D | 0.844 |
| 2 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.837 |
| 3 | TCGA-BH-A18V-06A-11R-A213-07 | — | D | 0.829 |
| 4 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.826 |
| 5 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.819 |
| 6 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.817 |
| 7 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.817 |
| 8 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.814 |
| 9 | SRR8613734 | — | D | 0.804 |
| 10 | TCGA-GC-A3WC-01A-31R-A22U-07 | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.060 | Inavolisib | — uncovered |